HC Wainwright Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) had its price objective reduced by HC Wainwright from $60.00 to $40.00 in ...
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...
Promising Efficacy and Safety of Jasper Therapeutics’ Briquilimab Boosts Buy Rating
Analyst Justin Zelin of BTIG reiterated a Buy rating on Jasper Therapeutics (JSPR – Research Report), reducing the price target to $64.00.Stay ...
Jasper Therapeutics: Promising Growth Potential in the Urticaria Market with Briquilimab’s Emerging Efficacy Profile
Analyst Etzer Darout from BMO Capital reiterated a Buy rating on Jasper Therapeutics (JSPR – Research Report) and keeping the price target at ...
Jane Street Group LLC Buys Shares of 13,354 Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Jane Street Group LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) during the third quarter, ...
Investing5d
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases
Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell ...
bovnews6d
Why Jasper Therapeutics Inc (JSPR) Stock is Currently -65.96% Off from Its 20-Day SMA?
Jasper Therapeutics Inc (JSPR) stock saw a decline, ending the day at $6.99 which represents a decrease of $-10.72 or -60.53% from the prior close of $17.71. The stock opened at $8.74 and touched a ...
Healio1d
Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab
Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
AOL7d
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
On Wednesday, Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous ...